Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on April 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). $175.0M gross equity offering through 87.5M shares priced at $2.00.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $175.0M gross equity offering through 87.5M shares priced at $2.00
- Potential additional dilution from 13.125M-share, 30-day underwriter option
- Proceeds earmarked for clinical trials, R&D, operating expenses and capital expenditures
- Expected April 16, 2026 closing remains subject to customary conditions
- Equity financing supports liquidity but dilutes existing shareholders; net proceeds reduced by offering costs
Item EX-99.1 · Exhibit EX-99.2
- Proposed $175 million underwritten common-stock offering, creating potential shareholder dilution
- Underwriters hold a 30-day option for an additional $26.25 million of shares
- Proceeds intended for clinical trials, R&D, corporate expenses, and capital expenditures
- Offering completion, size, and terms remain subject to market conditions and customary closing requirements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.